Cutaneous Manifestations of Viral Hepatitis

Current Infectious Disease Reports

Volumn 17, Issue 2, 2015, Pages

  Akhter, Ahmed ^a   Said, Adnan ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Extrahepatic manifestations; Gianotti Crosti syndrome; Hepatitis B; Hepatitis C; Lichen planus; Mixed cryoglobulinemia; Oral lichen planus; Polyarteritis nodosa; Porphyria cutanea tarda; Serum sickness

Indexed keywords

ANTIVIRAL THERAPY; CLINICAL FEATURE; CRYOGLOBULINEMIA; ERYTHEMA MULTIFORME; HEPATITIS B; HEPATITIS C; HUMAN; LICHEN PLANUS; LICHENOID ERUPTION; NECROTIZING ARTERITIS; NONHUMAN; PAPULAR ACRODERMATITIS; PATHOGENESIS; POLYARTERITIS NODOSA; PORPHYRIA CUTANEA TARDA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SERUM SICKNESS; SERUM SICKNESS LIKE SYNDROME; SKIN DEFECT; SKIN MANIFESTATION; SYSTEMIC VASCULITIS; VIRUS HEPATITIS; VIRUS REPLICATION;

EID: 84925729013     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0452-7     Document Type: Review

References (69)

1. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603.
2. Liaw YF, Tsai SL, Sheen IS, Chao M, Yeh CT, Hsieh SY, et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol. 1998;93(3):354–9. doi:10.1111/j.1572-0241.1998.00354.x.
3. Dienstag JL. Hepatitis B as an immune complex disease. Semin Liver Dis. 1981;1(1):45–57. doi:10.1055/s-2008-1063929.
4. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun. 2001;16(3):269–74. doi:10.1006/jaut.2000.0502.
5. Hollinger FB, Lau DT. Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin North Am. 2006;35(4):895–931. doi:10.1016/j.gtc.2006.10.002.
6. McElgunn PS. Dermatologic manifestations of hepatitis B virus infection. J Am Acad Dermatol. 1983;8(4):539–48.
7. Popp JW, Harrist TJ, Dienstag JL, Bhan AK, Wands JR, LaMont JT, et al. Cutaneous vasculitis associated with acute and chronic hepatitis. Arch Intern Med. 1981;141(5):623–9.
8. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13–21. doi:10.1002/hep.22881.
9. Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang. 1970;19(3):410–1.
10. Gocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen. Lancet. 1970;2(7684):1149–53.
11. Drüeke T, Barbanel C, Jungers P, Digeon M, Poisson M, Brivet F, et al. Hepatitis B antigen-associated periarteritis nodosa in patients undergoing long-term hemodialysis. Am J Med. 1980;68(1):86–90.
12. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.
13. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore). 1995;74(5):238–53.
14. Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis. 2004;8(2):403–18.
15. Shusterman N, London WT. Hepatitis B and immune-complex disease. N Engl J Med. 1984;310(1):43–6. doi:10.1056/NEJM198401053100110.
16. Guillevin L, Visser H, Noel LH, Pourrat J, Vernier I, Gayraud M, et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome—62 patients. J Rheumatol. 1993;20(8):1345–9.
17. McKee PH, JE JC, SR G Pathology of the skin.
18. Wartelle-Bladou C, Lafon J, Trépo C, Pichoud C, Picon M, Pellissier JF, et al. Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection. J Hepatol. 2001;34(5):774–9.
19. Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol. 1997;92(1):3–17.
20. Ishimaru Y, Ishimaru H, Toda G, Baba K, Mayumi M. An epidemic of infantile papular acrodermatitis (Gianotti’s disease) in Japan associated with hepatitis-B surface antigen subtype ayw. Lancet. 1976;1(7962):707–9.
21. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore). 2000;79(1):47–56.
22. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42(10):2204–12. doi:10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D.
23. Ferri C, Zignego AL. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol. 2000;12(1):53–60.
24. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum. 2002;46(3):585–97. doi:10.1002/art.10107.
25. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775–88.
26. Sene D, Ghillani-Dalbin P, Thibault V, Guis L, Musset L, Duhaut P, et al. Long-term course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol. 2004;31(11):2199–206.
27. Adinolfi LE, Utili R, Attanasio V, Zampino R, Ragone E, Tripodi MF, et al. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol. 1996;28(1):1–9.
28. Donada C, Crucitti A, Donadon V, Tommasi L, Zanette G, Crovatto M, et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat. 1998;5(3):179–85.
29. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117(6):1792–8. doi:10.1182/blood-2010-06-275818.
30. Darling JM, Lemon SM, Fried MW. Schiff’s diseases of the liver, 11th ed. In: Schiff ER, Maddrey WC, Sorrell MF, editors
31. Sène D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis. 2004;19(3–4):357–81.
32. Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5(10):528–40. doi:10.4254/wjh.v5.i10.528.
33. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med. 2014;6:25–33. doi:10.2147/HMER.S44375.
34. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10(8):444–54. doi:10.1016/j.autrev.2011.01.008. HCV-related MC is largely based on empirical data given the limited number of randomized controlled trials. This study was unique in that it used expert opinion from multiple medical specialties, given the nature of multi-organ involvement with MC, to recommend therapy for HCV-related MC.
35. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343–53. doi:10.1182/blood-2009-10-245878.
36. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia MT, Zignego AL. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol. 2003;21(6 Suppl 32):S78–84.
37. Chuang TY, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: a case–control study and meta-analysis of the literature. J Am Acad Dermatol. 1999;41(1):31–6.
38. Hussain I, Hepburn NC, Jones A, O’Rourke K, Hayes PC. The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol. 1996;21(4):283–5.
39. O’Reilly FM, Darby C, Fogarty J, O’Moore R, Courtney MG, O’Connor J, et al. Porphyrin metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed. 1996;12(1):31–3.
40. Sinclair PR, Bement WJ, Bonkovsky HL, Sinclair JF. Inhibition of uroporphyrinogen decarboxylase by halogenated biphenyls in chick hepatocyte cultures. Essential role for induction of cytochrome P-448. Biochem J. 1984;222(3):737–48.
41. Smith AG, Francis JE. Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload. Biochem J. 1987;246(1):221–6.
42. Frank J, Poblete-Gutiérrez P. Porphyria cutanea tarda—when skin meets liver. Best Pract Res Clin Gastroenterol. 2010;24(5):735–45. doi:10.1016/j.bpg.2010.07.002.
43. Ko HM, Hernandez-Prera JC, Zhu H, Dikman SH, Sidhu HK, Ward SC, et al. Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol. 2012;2012:740138. doi:10.1155/2012/740138.
44. Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology. 1997;44(14):525–8.
45. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol. 1995;22(2):249–50.
46. Pawlotsky JM, Dhumeaux D, Bagot M. Hepatitis C virus in dermatology. Rev Arch Dermatol. 1995;131(10):1185–93.
47. DeRossi SS, Ciarrocca KN. Lichen planus, lichenoid drug reactions, and lichenoid mucositis. Dent Clin North Am. 2005;49(1):77–89. doi:10.1016/j.cden.2004.08.004. viii.
48. Thornhill MH. Immune mechanisms in oral lichen planus. Acta Odontol Scand. 2001;59(3):174–7.
49. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, Mihailova AP, Hadjiev EA, Dikova RP, et al. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol. 2007;13(48):6518–28.
50. Carrozzo M, Gandolfo S, Carbone M, Colombatto P, Broccoletti R, Garzino-Demo P, et al. Hepatitis C virus infection in Italian patients with oral lichen planus: a prospective case–control study. J Oral Pathol Med. 1996;25(10):527–33.
51. Roy K, Bagg J. Hepatitis C virus and oral disease: a critical review. Oral Dis. 1999;5(4):270–7.
52. Zhou Y, Jiang L, Liu J, Zeng X, Chen QM. The prevalence of hepatitis C virus infection in oral lichen planus in an ethnic Chinese cohort of 232 patients. Int J Oral Sci. 2010;2(2):90–7. doi:10.4248/IJOS10028.
53. Carrozzo M, Gandolfo S. Oral diseases possibly associated with hepatitis C virus. Crit Rev Oral Biol Med. 2003;14(2):115–27.
54. Mega H, Jiang WW, Takagi M. Immunohistochemical study of oral lichen planus associated with hepatitis C virus infection, oral lichenoid contact sensitivity reaction and idiopathic oral lichen planus. Oral Dis. 2001;7(5):296–305.
55. Nagao Y, Sata M, Kage M, Kameyama T, Ueno T. Histopathological and immunohistochemical study of oral lichen planus-associated HCV infection. Eur J Intern Med. 2000;11(5):277–82.
56. Iraji F, Faghihi G, Asilian A, Siadat AH, Larijani FT, Akbari M. Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: a randomized clinical trial. J Res Med Sci. 2011;16(12):1578–82.
57. Carbone M, Arduino PG, Carrozzo M, Gandolfo S, Argiolas MR, Bertolusso G, et al. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Dis. 2009;15(3):235–43. doi:10.1111/j.1601-0825.2009.01516.x.
58. Pyrsopoulos NT, Reddy KR. Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep. 2001;3(1):71–8.
59. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007;49(2):89–106.
60. Voûte AB, Schulten EA, Langendijk PN, Kostense PJ, van der Waal I. Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Pathol. 1993;75(2):181–5.
61. Lodi G, Carrozzo M, Furness S, Thongprasom K. Interventions for treating oral lichen planus: a systematic review. Br J Dermatol. 2012;166(5):938–47. doi:10.1111/j.1365-2133.2012.10821.x. A systematic review including 28 randomized control trials that compared common therapies for OLP. There was no significant evidence to support superiority of either topical corticosteroids or topical calcineurin inhibitors in reducing pain associated with OLP.
62. Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev. 2011;7:CD001168. doi:10.1002/14651858.CD001168.pub2.
63. Corrocher G, Di Lorenzo G, Martinelli N, Mansueto P, Biasi D, Nocini PF, et al. Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. J Clin Periodontol. 2008;35(3):244–9. doi:10.1111/j.1600-051X.2007.01191.x.
64. Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(2):187–93. doi:10.1016/j.tripleo.2007.07.029.
65. Sonthalia S, Singal A. Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial. Int J Dermatol. 2012;51(11):1371–8. doi:10.1111/j.1365-4632.2012.05459.x.
66. Hodgson TA, Sahni N, Kaliakatsou F, Buchanan JA, Porter SR. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol. 2003;13(5):466–70.
67. Silverman S, Gorsky M, Lozada-Nur F, Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1991;72(6):665–70.
68. Verma KK, Mittal R, Manchanda Y. Azathioprine for the treatment of severe erosive oral and generalized lichen planus. Acta Derm Venereol. 2001;81(5):378–9.
69. Torti DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol. 2007;143(4):511–5. doi:10.1001/archderm.143.4.511.